EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer

Camila A Bach, Md Niamat Hossain, Ishan J Chaudhari, Cecilia E Verrillo, Nicole M Naranjo, Isabella Amoroso, Anna Testa, Samuel Sey, William K Kelly iD, Susan L Bellis, Aurelio Lorico, Ada G Blidner und 2 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0329014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Camila A Bach und 13 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Extracellular Vesicles, Prostatic Neoplasms, Sialyltransferases, Antigens, CD. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Altered cell surface glycosylation is a hallmark of cancer; among aberrant glycan structures, hypersialylated proteins contribute to disease progression. The enzyme ST6 β-galactoside α2,6-sialyltransferase 1 (ST6GAL1) mediates α2,6-linked sialylation of N-glycosylated proteins and is upregulated in many cancers, including prostate cancer (PrCa). We propose that ST6GAL1 may be released by cancer cells in small extracellular vesicles (sEVs) in the PrCa tumor microenvironment to potentially modulate cell surface sialylation in recipient cells. We isolated sEVs from PrCa cells by density gradient separation and characterized them by nanoparticle tracking analysis using ZetaView and immunoblotting analysis. We identified ST6GAL1 in both its membrane-bound and soluble forms, both active, in circulating sEVs from healthy donors and patients with PrCa. ST6GAL1 is also expressed in human PrCa cells (PC3, DU145, and C4-2B), and in murine cells (TRAMP-C2 and RM1) at different levels, which correlate with aggressive cell phenotypes. In addition to classic sEV markers, such as CD9, TSG101 and Syntenin, sEVs isolated from PrCa cell lines express PDL1, an immune checkpoint ligand. The soluble ST6GAL1 form is present in the sEVs released from DU145 and PC3 cells and can be transferred via sEVs to recipient PrCa cells. This transfer is prevented by expression of Nogo-66 receptor homolog 2 (NgR2) and β3 integrin, which are elevated in the aggressive neuroendocrine phenotype of the disease. The soluble form is absent in the sEVs released from the bone metastatic line C4-2B, which only contains the membrane-bound form. Our results suggest that ST6GAL1 in sEVs derived from PrCa cells may potentially play a role in promoting bone metastasis by facilitating the formation of the pre-metastatic niche.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesProstatic NeoplasmsSialyltransferasesAntigens, CDN-Acetylneuraminic AcidMaleHumansAnimalsMiceCell Line, TumorTumor MicroenvironmentGlycosylationbeta-D-Galactoside alpha 2-6-Sialyltransferase

Substanzen

SialyltransferasesST6GAL1 protein, humanAntigens, CDN-Acetylneuraminic Acidbeta-D-Galactoside alpha 2-6-Sialyltransferase

Autor:innen und Institutionen

  • Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
  • Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
  • Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
  • Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina.
  • Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.
  • Department of Cell, Developmental and Integrative Biology, University of Alabama, Birmingham, Alabama, United States of America.

ORCID-Profile: William K Kelly, Lucia R Languino

Förderung

  • U.S. Department of Defense
  • National Cancer Center

Zitieren

APA

Bach, C. A., Hossain, M. N., Chaudhari, I. J., Verrillo, C. E., Naranjo, N. M., Amoroso, I., Testa, A., Sey, S., Kelly, W. K., Bellis, S. L., Lorico, A., Blidner, A. G., Rabinovich, G. A., & Languino, L. R. (2025). A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. PLOS One. https://doi.org/10.1371/journal.pone.0329014

Vancouver

Bach CA, Hossain MN, Chaudhari IJ, Verrillo CE, Naranjo NM, Amoroso I, et al. A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. PLOS One. 2025. doi:10.1371/journal.pone.0329014

BibTeX
@article{Bach2025,
  author = {Bach, Camila A and Hossain, Md Niamat and Chaudhari, Ishan J and Verrillo, Cecilia E and Naranjo, Nicole M and Amoroso, Isabella and Testa, Anna and Sey, Samuel and Kelly, William K and Bellis, Susan L and Lorico, Aurelio and Blidner, Ada G and Rabinovich, Gabriel A and Languino, Lucia R},
  title = {A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0329014}
}
Kostenlos starten →